ResMed CFO Brett Sandercock to retire; Aaron Bloomer named successor effective May 4
ResMed said CFO Brett Sandercock will retire, with Aaron Bloomer, formerly CFO of Exact Sciences, taking over as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer effective May 4, 2026. The company said the retirement was not the result of any disagreement on operations, policies or practices, and it reiterated its fiscal 2026 outlook alongside the announcement.
Key points
- Sandercock serves as CFO until May 4, 2026, then as Special Advisor to Chairman and CEO Mick Farrell through December 31, 2026, and in a consulting role through December 31, 2027.
- Bloomer, age 40, receives a $725,000 base salary, a $150,000 sign-on bonus and a $3,300,000 long-term performance equity grant when he joins.
- Bloomer is also eligible for a $3,300,000 equity grant in November 2026 for fiscal year 2027.
- ResMed reiterated fiscal 2026 outlook, including gross margin of 62-63%.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.